参考文献/References:
[1]Lee DM,Weinblatt ME.Rheumatoid arthritis[J].Lancet,2001,358(9285):903-911.[2]Hernández-Breijo B,Plasencia-Rodríguez C,Navarro-Compán V,et al.Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naive B Cells in Patients With Rheumatoid Arthritis[J].ront Med (Lausanne),2021,8:683990.[3]Tono T,Aihara S,Hoshiyama T,et al.Effects of CTLA4-Ig on human monocytes[J].Inflamm Regen,2017,37:24.[4]van der Helm-van Mil AH,Verpoort KN,Breedveld FC,et al.Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis[J].Arthritis Res Ther,2005,7(5):R949-R958.[5]Riedemann JP,Mu?oz S,Kavanaugh A.The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis--a systematic review[J].Clin Exp Rheumatol,2005,23(5 Suppl 39):S69-S76.[6]Wu X,Liu Y,Jin S,et al.Single-cell sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis[J].Nat Commun,2021,12(1):4977.[7]McInnes IB,Schett G.Pathogenetic insights from the treatment of rheumatoid arthritis[J].Lancet,2017,389(10086):2328-2337.[8]Pratt AG,Isaacs JD.Seronegative rheumatoid arthritis: pathogenetic and therapeutic aspects[J].Best Pract Res Clin Rheumatol,2014,28(4):651-659.[9]Niewold TB,Harrison MJ,Paget SA.Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis[J].QJM,2007,100(4):193-201.[10]Hecht C,Englbrecht M,Rech J,et al.Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA[J].Ann Rheum Dis,2015,74(12):2151-2156.[11]Lin Q,Zhou B,Song X,et al.Genetic variant in SPAG16 is associated with the susceptibility of ACPA-positive rheumatoid arthritis possibly via regulation of MMP-3[J].J Orthop Surg Res,2022,17(1):511.[12]Ajeganova S,Humphreys JH,Verheul MK,et al.Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts[J].Ann Rheum Dis,2016,75(11):1924-1932.[13]Smolen JS,Landewé RBM,Bijlsma JWJ,et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update[J].Ann Rheum Dis,2020,79(6):685-699.[14]Hosseini A,Gharibi T,Marofi F,et al.CTLA-4: From mechanism to autoimmune therapy[J].Int Immunopharmacol,2020,80:106221.[15]Moreland L,Bate G,Kirkpatrick P.Abatacept[J].Nat Rev Drug Discov,2006,5(3):185-186.[16]Kremer JM,Westhovens R,Leon M,et al.Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig[J].N Engl J Med,2003,349(20):1907-1915.[17]Pieper J,Herrath J,Raghavan S,et al.CTLA4-Ig （abatacept） therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients[J].BMC Immunology,2013,14(1):34.[18]Bonelli M,Ferner E,G?觟schl L,et al.Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis[J].Arthritis Rheum,2013,65(3):599-607.[19]Emery P,Deodhar A,Rigby WF,et al.Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE))[J].Ann Rheum Dis,2010,69(9):1629-1635.[20]Platt AM,Gibson VB,Patakas A,et al.Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells[J].J Immunol,2010,185(3):1558-1567.[21]Matsubara T,Inoue H,Nakajima T,et al.Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study[J].RMD Open,2018,4(2):e000813.[22]Jansen DTSL,Emery P,Smolen JS,et al.Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study[J].RMD Open,2018,4(1):e000564.[23]Alten R,Burkhardt H,Feist E,et al.Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs:a descriptive analysis of data from interventional trials and the real-world setting[J].Arthritis Res Ther,2018,20(1):1.[24]Weinblatt ME,Schiff M,Valente R,et al.Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study[J].Arthritis Rheum,2013,65(1):28-38.[25]Genovese MC,Schiff M,Luggen M,et al.Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy[J].Ann Rheum Dis,2008,67(4):547-554.[26]Harrold LR,Litman HJ,Connolly SE,et al.Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry[J].Rheumatol Ther,2019,6(2):217-230.[27]Westhovens R,Connolly SE,Margaux J,et al.Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study[J].Rheumatol Int,2020,40(9):1409-1421.[28]Elmedany SH,Mohamed AE,Galil SMA.Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis[J].Clin Rheumatol,2019,38(8):2109-2117.[29]Schiff M,Keiserman M,Codding C,et al.Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate[J].Ann Rheum Dis,2008,67(8):1096-1103.[30]Smitten AL,Choi HK,Hochberg MC,et al.The risk of hospitalized infection in patients with rheumatoid arthritis[J].J Rheumatol,2008,35(3):387-393.[31]Simon TA,Thompson A,Gandhi KK,et al.Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis[J].Arthritis Res Ther,2015,17(1):212.[32]Kremers HM,Crowson CS,Therneau TM,et al.High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study[J].Arthritis Rheum,2008,58(8):2268-2274.[33]Totoson P,Maguin-Gaté K,Prati C,et al.Mechanisms of endothelial dysfunction in rheumatoid arthritis: lessons from animal studies[J].Arthritis Res Ther,2014,16(1):202.[34]Benucci M,Bandinelli F,Damiani A,et al.Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis[J].J Inflamm Res,2018,11:247-252.[35]Wadstr?觟m H,Frisell T,Askling J.Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden[J].JAMA Intern Med,2017,177(11):1605-1612.[36]Simon TA,Boers M,Hochberg M,et al.Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study[J].Arthritis Res Ther,2019,21(1):228.[37]Kremer JM,Genant HK,Moreland LW,et al.Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate[J].Arthritis Rheum,2008,58(4):953-963.[38]Cabral VP,Andrade CA,Passos SR,et al.Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies[J].Rev Bras Reumatol Engl Ed,2016,56(6):543-550.[39]Ozen G,Pedro S,Schumacher R,et al.Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study[J].Arthritis Res Ther,2019,21(1):141.[40]Petro AD,Dougherty J,England BR,et al.Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis[J].Int Immunopharmacol,2021,91:107260.[41]Alemao E,Postema R,Elbez Y,et al.Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis[J].Clin Exp Rheumatol,2020,38(3):455-466.[42]Alten R,Nüβlein HG,Mariette X,et al.Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic na?ve: 6-month results from a real-world, international, prospective study[J].RMD Open,2017,3(1):e000345.[43]Sokolove J,Schiff M,Fleischmann R,et al.Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab:2-year results from the AMPLE trial[J].Ann Rheum Dis,2016,75(4):709-714.[44]Scott DL,Pugner K,Kaarela K,et al.The links between joint damage and disability in rheumatoid arthritis[J].Rheumatology (Oxford),2000,39(2):122-132.[45]Kremer JM,Peterfy C,Russell AS,et al.Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial[J].J Rheumatol,2014,41(6):1077-1087.[46]Kremer JM,Genant HK,Moreland LW,et al.Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial[J].Ann Intern Med,2006,144(12):865-876.[47]Endo Y,Koga T,Kawashiri SY,et al.Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan[J].Scand J Rheumatol,2020,49(1):13-17.
相似文献/References:
[1]章 豫,艾艳红.蛋白质代谢变化、血脂与类风湿关节炎患者动脉粥样硬化的相关性研究[J].医学信息,2018,31(02):84.[doi:10.3969/j.issn.1006-1959.2018.02.028]
ZHANG Yu,AI Yan-hong.Correlation between Changes of Protein Metabolism,Serum Lipids and Atherosclerosis in Patients with Rheumatoid Arthritis[J].Journal of Medical Information,2018,31(09):84.[doi:10.3969/j.issn.1006-1959.2018.02.028]
[2]黄 娟,叶福银.类风湿关节炎合并腹痛1例[J].医学信息,2018,31(08):188.[doi:10.3969/j.issn.1006-1959.2018.08.070]
[3]杜 敏,李 娜.抗CCP抗体与RF联合检测在类风湿关节炎早期诊断中的意义[J].医学信息,2019,32(06):177.[doi:10.3969/j.issn.1006-1959.2019.06.058]
DU Min,LI Na.Significance of Combined Detection of Anti-CCP Antibody and RF in Early Diagnosis of Rheumatoid Arthritis[J].Journal of Medical Information,2019,32(09):177.[doi:10.3969/j.issn.1006-1959.2019.06.058]
[4]万 昭,向 阳.中药延缓类风湿关节炎骨破坏的研究进展[J].医学信息,2019,32(07):36.[doi:10.3969/j.issn.1006-1959.2019.07.013]
WAN Zhao,XIANG Yang.Research Progress on Traditional Chinese Medicine for Delaying Bone Destruction of Rheumatoid Arthritis[J].Journal of Medical Information,2019,32(09):36.[doi:10.3969/j.issn.1006-1959.2019.07.013]
[5]杨海红,星 霞,李雪莹,等.类风湿关节炎患者焦虑及抑郁情绪与
疾病活动度的相关性[J].医学信息,2019,32(18):110.[doi:10.3969/j.issn.1006-1959.2019.18.036]
YANG Hai-hong,XING Xia,LI Xue-ying,et al.Correlation between Anxiety and Depression and Disease Activity
in Patients with Rheumatoid Arthritis[J].Journal of Medical Information,2019,32(09):110.[doi:10.3969/j.issn.1006-1959.2019.18.036]
[6]郑 伟.诱骗受体3γ-干扰素和抗环瓜氨酸肽抗体在风湿性关节炎患者血清中的表达[J].医学信息,2019,32(19):97.[doi:10.3969/j.issn.1006-1959.2019.19.029]
ZHENG Wei.Expression of Decoy Receptor 3γ-Interferon and Anti-Cyclic Citrullinated Peptide Antibody in Serum of Patients with Rheumatoid Arthritis[J].Journal of Medical Information,2019,32(09):97.[doi:10.3969/j.issn.1006-1959.2019.19.029]
[7]王 鹏,郝敬春,厉志洪,等.超微血管成像技术评估类风湿关节炎手指关节
亚临床炎及分布特点[J].医学信息,2019,32(14):98.[doi:10.3969/j.issn.1006-1959.2019.14.030]
WANG Peng,HAO Jing-chun,LI Zhi-hong,et al.Evaluation of Subclinical Inflammation and Distribution of Finger Joints in
Rheumatoid Arthritis by Ultra-Microvascular Imaging[J].Journal of Medical Information,2019,32(09):98.[doi:10.3969/j.issn.1006-1959.2019.14.030]
[8]丁宇康.化瘀通痹方联合甲氨蝶呤治疗难治性类风湿关节炎的效果[J].医学信息,2019,32(24):171.[doi:10.3969/j.issn.1006-1959.2019.24.063]
DING Yu-kang.Observation of Huayu Tongbi Recipe Combined with Methotrexate in the Treatment of Refractory Rheumatoid Arthritis[J].Journal of Medical Information,2019,32(09):171.[doi:10.3969/j.issn.1006-1959.2019.24.063]
[9]陈 婧,高晓瑜.类风湿关节炎多关节病变的超声诊断[J].医学信息,2020,33(16):175.[doi:10.3969/j.issn.1006-1959.2020.16.058]
CHEN Jing,GAO Xiao-Yu.Ultrasonic Diagnosis of Rheumatoid Arthritis Polyarthropathy[J].Journal of Medical Information,2020,33(09):175.[doi:10.3969/j.issn.1006-1959.2020.16.058]
[10]王宝娟,辛昊洋,李 月.基于网络药理学探讨木防己汤治疗类风湿关节炎的作用机制[J].医学信息,2022,35(23):25.[doi:10.3969/j.issn.1006-1959.2022.23.005]
WANG Bao-juan,XIN Hao-yang,LI Yue.Study on Mechanism of Mufangji Decoction in the Treatment of Rheumatoid Arthritis Based on Network Pharmacology[J].Journal of Medical Information,2022,35(09):25.[doi:10.3969/j.issn.1006-1959.2022.23.005]